BioWorld
-
Wuhan coronavirus is emergency in China, not yet international concern: WHO
-
Ionctura closes series A for next-generation dual-targeting cancer therapies
-
Soon-Shiong’s Nantkwest, Immunitybio still chasing cancer breakthroughs
-
Australia’s TGA proposes fee increases to implement recent drug, device reforms
-
Ireland’s embrace of genomics remains tentative
-
Born again: Neurotrope back in the game with bryostatin-1 in Alzheimer’s
-
WHO needs more information on novel coronavirus infection before declaring emergency
-
Significant year of growth for regenerative medicine sector
-
Kintai’s good PEMmanship draws gutsy map to obesity and more
BioWorld MedTech
-
Novel Dx companies start to see a better path with payers, but continue to work all the angles
-
AI, data science companies strut their stuff at PMWC
-
Study of paclitaxel devices in infrapopliteal arteries resurrects mortality controversy
-
Tennor’s prosthetic joint infections therapy, TNP-2092, set to start phase III soon
-
BioWorld MedTech’s Diagnostics Extra for Jan. 23, 2020
-
BioWorld MedTech Patent Highlights: Week 3
-
Thiel calls for improving research grant, regulatory processes to enhance scientific innovation
-
Verily highlights diabetes care, Project Baseline even as related partnerships are restructured
-
FDA greenlights Ra Medical’s DABRA atherectomy trial
BioWorld Asia
-
Chi-Med’s surufatinib phase III trial halted early after meeting primary endpoint in advanced pancreatic NET
-
China’s I-Mab goes public in targeted range for $103.7M; after-market deep Zai?
-
Industry: Trade agreement important first step toward fairer Chinese market
-
Noxopharm spin-off Nyrada lists on ASX raising AU$8.5 million in oversubscribed IPO
-
Bionetix secures $9.33M in series B funding for AML/MDS and glaucoma treatment
-
Oncologie boosts pipeline with phase II-ready bispecific candidate in Mereo deal
-
Miracogen expands ADC deal with Synaffix
-
China promotes real-world evidence in R&D and approval with new guidelines
-
Aum Biosciences partners with Cyclica for cancer therapies development
